Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aclaris Therapeutics (ACRS) EBIT (2017 - 2025)

Aclaris Therapeutics has reported EBIT over the past 9 years, most recently at -$22.7 million for Q4 2025.

  • Quarterly results put EBIT at -$22.7 million for Q4 2025, up 77.19% from a year ago — trailing twelve months through Dec 2025 was -$76.4 million (up 46.19% YoY), and the annual figure for FY2025 was -$76.4 million, up 46.19%.
  • EBIT for Q4 2025 was -$22.7 million at Aclaris Therapeutics, down from -$17.1 million in the prior quarter.
  • Over the last five years, EBIT for ACRS hit a ceiling of -$4.0 million in Q4 2023 and a floor of -$99.7 million in Q4 2024.
  • Median EBIT over the past 5 years was -$20.6 million (2021), compared with a mean of -$24.8 million.
  • Biggest five-year swings in EBIT: surged 86.08% in 2023 and later tumbled 2362.94% in 2024.
  • Aclaris Therapeutics' EBIT stood at -$22.9 million in 2021, then dropped by 27.02% to -$29.1 million in 2022, then surged by 86.08% to -$4.0 million in 2023, then tumbled by 2362.94% to -$99.7 million in 2024, then skyrocketed by 77.19% to -$22.7 million in 2025.
  • The last three reported values for EBIT were -$22.7 million (Q4 2025), -$17.1 million (Q3 2025), and -$18.4 million (Q2 2025) per Business Quant data.